|

Olaparib 150 MG Clinical Trials

2 actively recruiting trials

Also known as: BR2022

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • Boryung Pharmaceutical Co., Ltd1
  • Azienda Ospedaliero-Universitaria di Modena1

Indications

  • Cancer2
  • Advanced Pancreatic Cancer1
  • Metastatic Pancreatic Cancer1
  • Ovarian Cancer1

Other2 trials

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
Phase 1
Olaparib in PALB2 Advanced Pancreatic Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.